Share this article
DAVIS, Calif., March 11, 2021 /PRNewswire/ Evolve BioSystems, Inc. today announces that its product, activated
B. infantis EVC001, will be used in one of the largest international clinical studies on preventing type 1 diabetes (T1D) in genetically predisposed children. The randomized, controlled, double-blind, multicenter trial will be conducted across eight major research centers in five European countries.
The Leona M. and Harry B. Helmsley Charitable Trust is funding the study and the continuation of the established newborn screening with more than $30 million.
The SINT1A study (
Supplementation with B. infantis for Mitigation of Type 1 Diabetes Autoimmunity) aims to show that the daily administration of activated
Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)
Presentation of Phase 1/2 LIBRETTO-001 trial data will highlight safety and efficacy data of Retevmo® (selpercatinib) in the treatment of RET fusion-positive cancers outside of lung and thyroid cancer
Preclinical characterization data will be presented for oral SERD, BCL2 inhibitor, next-generation KRAS-G12C, and RET inhibitors
News provided by
Share this article
Share this article
INDIANAPOLIS, March 10, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually April 10-15, 2021. During the meeting, Lilly Oncology will present data from a study exploring safety and efficacy of its selective RET-kinase inhibitor Retevmo
ORCA Therapeutics B.V.
, a clinical-stage biopharmaceutical company developing oncolytic viruses to treat solid tumors, is pleased to announce that, upon review of all safety data from the fully enrolled, low- and mid-dose patient cohorts of the ongoing Phase 1/2a clinical study of ORCA-010 in treatment-naïve patients with localized prostate cancer, the independent Data and Safety Monitoring Board (DSMB) unanimously recommended the continuation of the study without modification. From this recommendation, ORCA Therapeutics will initiate administration of the highest scheduled dose level of ORCA-010 in the single dose part of the study.
Following this recommendation, ORCA Therapeutics B.V. has commenced enrollment in the highest-dose arm of the dose-escalation phase of this study, with the first patient scheduled for administration in March 2021. Upon conclusion of enrollment in the highest study arm, DSMB will conduct an additional review on ORCA-010 prior to starting the repeat
/PRNewswire/ Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world s largest pure-play IVD companies dedicated to transforming patient care, today.